2-(3-羟基-苄基)-丁酸 | 328288-90-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 2-(3-羟基-苄基)-丁酸
• 英文名称: 2-(3-hydroxybenzyl)butanoic acid
• 英文别名: 2-(3-hydroxy-benzyl)-butyric acid；2-(3-Hydroxy-benzyl)-buttersaeure；2-[(3-Hydroxyphenyl)methyl]butanoic acid
• CAS: 328288-90-0
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: APDIHWXZDGCAGL-UHFFFAOYSA-N

物化性质

• 沸点：
  364.3±17.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  、 2-(3-羟基-苄基)-丁酸 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain

  摘要：

  Rhodesain, the major cathepsin L-like cysteine protease in the protozoan Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness, is a well-validated drug target. In this work, we used a fragment-based approach to identify inhibitors of this cysteine protease, and identified inhibitors of T. brucei. To discover inhibitors active against rhodesain and T. brucei, we screened a library of covalent fragments against rhodesain and conducted preliminary SAR studies. We envision that in vitro enzymatic assays will further expand the use of the covalent tethering method, a simple fragment-based drug discovery technique to discover covalent drug leads. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.08.074
• 作为产物：
  描述：

  2-甲基丁酸 在 sodium phosphate dibasic dodecahydrate 、 N-乙酰-Β-丙氨酸 、 palladium diacetate 、 三溴化硼 、 silver(l) oxide 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 2-(3-羟基-苄基)-丁酸
  参考文献：
  名称：

  Pd催化的丙酸和相关脂肪酸的β-C（sp3）-H芳基化

  摘要：

  据报道，丙酸和相关的α-支链脂肪酸的β-C（sp 3）-H芳基化反应普遍采用钯催化方案。通过使用N-乙酰基-β-丙氨酸作为配体，我们的方案可提供多种芳基化产物。值得注意的是，具有挑战性的底物丙酸可以通过合成获得有用的收率，而丙酸由于其索普-英戈尔德效应而没有任何加速作用，因此可以用作底物。此外，还演示了该协议的可伸缩性和综合适用性。

  DOI：

  10.1002/chem.201705449

文献信息

• Compounds for the treatment of metabolic disorders
  申请人：Hodge L. Kevin

  公开号：US20060247309A1

  公开（公告）日：2006-11-02

  Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, artherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 4 or 5; q is 0 or 1; t is 0 or 1; R 2 is alkyl from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by or 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloaldyl having from 3 to 6 ring carbon atoms wherein the cycloaldyl is unsubstitited or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compounds of formula (I) by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

  本发明揭示了用于治疗各种代谢性疾病的药剂，例如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝病、消瘦症、肥胖症、动脉粥样硬化和动脉硬化。其中，公式（I）中，n为1或2；m为0、1、2、4或5；q为0或1；t为0或1；R2为1至3个碳原子的烷基；R3为氢、卤素、1至3个碳原子的烷基或1至3个碳原子的烷氧基；A为苯基，未取代或被1或2个基取代，所述基选择自：卤素、1或2个碳原子的烷基、全氟甲基、1或2个碳原子的烷氧基和全氟甲氧基；或者为具有3至6个环碳原子的环烷基，其中所述环烷基未取代或1或2个环碳原子被独立地甲基或乙基单取代；或者为具有1或2个从N、S和O中选择的环杂原子的5或6元杂环芳基，所述杂环芳基通过一个环碳原子与公式（I）中余下的化合物共价结合；R1为氢或1或2个碳原子的烷基。或者，当R1为氢时，生物活性剂可以是公式（I）化合物的药学上可接受的盐。
• COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Hodge L. Kirvin

  公开号：US20080015254A1

  公开（公告）日：2008-01-17

  Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 4, or 5; q is 0 or 1; t is 0 or 1; R 2 is alkyl having from 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R 1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

  本发明揭示了用于治疗各种代谢性疾病的药物，例如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝病、消瘦、肥胖症、动脉硬化和动脉粥样硬化等。其中n为1或2；m为0、1、2、4或5；q为0或1；t为0或1；R2为具有1至3个碳原子的烷基；R3为氢、卤素、具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基；A为苯基，未取代或取代为1或2个选自：卤素、具有1或2个碳原子的烷基、全氟甲基、具有1或2个碳原子的烷氧基和全氟甲氧基的基团；或具有3至6个环碳原子的环烷基，其中环烷基未取代或一个或两个环碳原子独立地被甲基或乙基单取代；或具有1或2个选自N、S和O的环杂芳基，且所述杂芳环通过一个环碳原子与化合物的其余部分共价结合；以及R1为氢或具有1或2个碳原子的烷基。或者，当R1为氢时，化合物I的药物活性剂可以是其药学上可接受的盐。
• Compound For The Treatment Of Metabolic Disorders
  申请人：Wellstat Therapeutics Corporation

  公开号：EP2266946A2

  公开（公告）日：2010-12-29

  Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 4, or 5; q is 0 or 1; t is 0 or 1; R2 is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms. Alternatively, when R1 is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.

  本研究公开了可用于治疗各种代谢紊乱的制剂，如胰岛素抵抗综合征、糖尿病、高脂血症、脂肪肝、恶病质、肥胖症、动脉粥样硬化和动脉硬化。 其中 n 是 1 或 2；m 是 0、1、2、4 或 5；q 是 0 或 1；t 是 0 或 1；R2 是具有 1 至 3 个碳原子的烷基；R3 是氢、卤素、具有 1 至 3 个碳原子的烷基或具有 1 至 3 个碳原子的烷氧基； A 是苯基，未被取代或被 1 或 2 个基团取代，这些基团选自：卤代、具有 1 或 2 个碳原子的烷基、全氟甲基、具有 1 或 2 个碳原子的烷氧基，以及 或具有 3 至 6 个环碳原子的环烷基，其中环烷基未被取代，或 1 或 2 个环碳独立地被甲基或乙基单取代；或具有 1 或 2 个选自 N、S 和 O 的环杂原子的 5 或 6 位杂芳环，且该杂芳环通过一个环碳与式 I 化合物的其余部分共价结合；以及 R1 是氢或具有 1 或 2 个碳原子的烷基。或者，当 R1 为氢时，生物活性剂可以是式 I 化合物的药学上可接受的盐。
• X-Ray Diagnostics. VII. Cholecystographic Agents¹
  作者：Domenick Papa、Helen F. Ginsberg、Ilse Lederman、Virginia DeCamp

  DOI：10.1021/ja01101a029

  日期：1953.3
• EP1601251A4
  申请人：——

  公开号：EP1601251A4

  公开（公告）日：2007-03-28